絞り込み

16641

広告

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

著者 Rolinski M , Fox C , Maidment I , McShane R
Cochrane Database Syst Rev.2012 ; 3():CD006504.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Headington, Oxford, UK, OX3 9DU.

スターを付ける スターを付ける     (557view , 0users)

Full Text Sources

Medical

Miscellaneous

Previous Cochrane reviews have considered the use of cholinesterase inhibitors in both Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB). The clinical features of DLB and PDD have much in common and are distinguished primarily on the basis of whether or not parkinsonism precedes dementia by more than a year. Patients with both conditions have particularly severe deficits in cortical levels of the neurotransmitter acetylcholine. Therefore, blocking its breakdown using cholinesterase inhibitors may lead to clinical improvement.
PMID: 22419314 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード